LY6K: Increased expression of LY6K has also been reported in metastatic ER positive breast cancer (41–43), esophageal squamous cancer (44), gingivobuccal cancers (45), bladder cancer (46), and lung cancer (47). Here, LY6K is linked to lung carcinoma.